Epidermal Growth Factor Receptor Regulates Beta-catenin Location, Stability, and Transcriptional Activity in Oral Cancer

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2010 Mar 23

PMID 20302655

Citations 45

Authors

Chien-Hsing Lee

Hsing-Wen Hung

Pei-Hsin Hung

Yi-Shing Shieh

Affiliations

Soon will be listed here.

Abstract

Background: Many cancerous cells accumulate beta-catenin in the nucleus. We examined the role of epidermal growth factor receptor (EGFR) signaling in the accumulation of beta-catenin in the nuclei of oral cancer cells.

Results: We used two strains of cultured oral cancer cells, one with reduced EGFR expression (OECM1 cells) and one with elevated EGFR expression (SAS cells), and measured downstream effects, such as phosphorylation of beta-catenin and GSK-3beta, association of beta-catenin with E-cadherin, and target gene regulation. We also studied the expression of EGFR, beta-catenin, and cyclin D1 in 112 samples of oral cancer by immunostaining. Activation of EGFR signaling increased the amount of beta-catenin in the nucleus and decreased the amount in the membranes. EGF treatment increased phosphorylation of beta-catenin (tyrosine) and GSK-3beta(Ser-(9), resulting in a loss of beta-catenin association with E-cadherin. TOP-FLASH and FOP-FLASH reporter assays demonstrated that the EGFR signal regulates beta-catenin transcriptional activity and mediates cyclin D1 expression. Chromatin immunoprecipitation experiments indicated that the EGFR signal affects chromatin architecture at the regulatory element of cyclin D1, and that the CBP, HDAC1, and Suv39h1 histone/chromatin remodeling complex is involved in this process. Immunostaining showed a significant association between EGFR expression and aberrant accumulation of beta-catenin in oral cancer.

Conclusions: EGFR signaling regulates beta-catenin localization and stability, target gene expression, and tumor progression in oral cancer. Moreover, our data suggest that aberrant accumulation of beta-catenin under EGFR activation is a malignancy marker of oral cancer.

Citing Articles

Dickkopf-1 promotes tumor progression of gefitinib- resistant non-small cell lung cancer through cancer cell-fibroblast interactions.

Choi M, Choi Y, Lee Y, Lee Y, Chung J, Kang K Exp Hematol Oncol. 2025; 14(1):24.

PMID: 40025612 PMC: 11871833. DOI: 10.1186/s40164-025-00616-9.

Piperonylic Acid Promotes Hair Growth by Activation of EGFR and Wnt/β-Catenin Pathway.

Han S, Jo K, Kim Y, Kim K Int J Mol Sci. 2024; 25(19).

PMID: 39409103 PMC: 11476903. DOI: 10.3390/ijms251910774.

Primary cilia-associated signalling in squamous cell carcinoma of head and neck region.

Putnova I, Putnova B, Hurnik P, Stembirek J, Buchtova M, Koliskova P Front Oncol. 2024; 14:1413255.

PMID: 39234399 PMC: 11372790. DOI: 10.3389/fonc.2024.1413255.

3D organoid cultivation improves the maturation and functional differentiation of cholangiocytes from human pluripotent stem cells.

Budi N, Lai W, Huang Y, Ho H Front Cell Dev Biol. 2024; 12:1361084.

PMID: 39040044 PMC: 11260683. DOI: 10.3389/fcell.2024.1361084.

Biomarkers of epithelial-mesenchymal transition: E-cadherin and beta-catenin in malignant transformation of oral lesions.

Yim I, Laronde D Can J Dent Hyg. 2024; 58(2):111-119.

PMID: 38974823 PMC: 11223640.

References

Zinser G, Leonis M, Toney K, Pathrose P, Thobe M, Kader S . Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res. 2006; 66(24):11967-74. DOI: 10.1158/0008-5472.CAN-06-2473. View

Kishida S, Yamamoto H, Ikeda S, Kishida M, Sakamoto I, Koyama S . Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin. J Biol Chem. 1998; 273(18):10823-6. DOI: 10.1074/jbc.273.18.10823. View

Liu S, Chang L, Pan L, Hung Y, Lee C, Shieh Y . Clinicopathologic significance of tumor cell-lined vessel and microenvironment in oral squamous cell carcinoma. Oral Oncol. 2007; 44(3):277-85. DOI: 10.1016/j.oraloncology.2007.02.007. View

Barker N, Morin P, Clevers H . The Yin-Yang of TCF/beta-catenin signaling. Adv Cancer Res. 1999; 77:1-24. DOI: 10.1016/s0065-230x(08)60783-6. View

Willert K, Jones K . Wnt signaling: is the party in the nucleus?. Genes Dev. 2006; 20(11):1394-404. DOI: 10.1101/gad.1424006. View

Akervall J, Michalides R, Mineta H, Balm A, Borg A, Dictor M . Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer. 1997; 79(2):380-9. View

Brembeck F, Rosario M, Birchmeier W . Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev. 2005; 16(1):51-9. DOI: 10.1016/j.gde.2005.12.007. View

Hamaguchi M, Matsuyoshi N, Ohnishi Y, Gotoh B, Takeichi M, Nagai Y . p60v-src causes tyrosine phosphorylation and inactivation of the N-cadherin-catenin cell adhesion system. EMBO J. 1993; 12(1):307-14. PMC: 413207. DOI: 10.1002/j.1460-2075.1993.tb05658.x. View

Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T . AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet. 2000; 24(3):245-50. DOI: 10.1038/73448. View

10.

Iwao K, Nakamori S, Kameyama M, Imaoka S, Kinoshita M, Fukui T . Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res. 1998; 58(5):1021-6. View

11.

Ni C, Murphy M, Golde T, Carpenter G . gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science. 2001; 294(5549):2179-81. DOI: 10.1126/science.1065412. View

12.

Gordon M, Nusse R . Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem. 2006; 281(32):22429-33. DOI: 10.1074/jbc.R600015200. View

13.

Ihara A, Koizumi H, Hashizume R, Uchikoshi T . Expression of epithelial cadherin and alpha- and beta-catenins in nontumoral livers and hepatocellular carcinomas. Hepatology. 1996; 23(6):1441-7. DOI: 10.1053/jhep.1996.v23.pm0008675162. View

14.

Lo H, Xia W, Wei Y, Ali-Seyed M, Huang S, Hung M . Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res. 2005; 65(1):338-48. View

15.

Mareel M, Behrens J, Birchmeier W, De Bruyne G, Vleminckx K, Hoogewijs A . Down-regulation of E-cadherin expression in Madin Darby canine kidney (MDCK) cells inside tumors of nude mice. Int J Cancer. 1991; 47(6):922-8. DOI: 10.1002/ijc.2910470623. View

16.

Yochum G, Cleland R, Goodman R . A genome-wide screen for beta-catenin binding sites identifies a downstream enhancer element that controls c-Myc gene expression. Mol Cell Biol. 2008; 28(24):7368-79. PMC: 2593444. DOI: 10.1128/MCB.00744-08. View

17.

Pukkila M, Virtaniemi J, Kumpulainen E, Pirinen R, Johansson R, Valtonen H . Nuclear beta catenin expression is related to unfavourable outcome in oropharyngeal and hypopharyngeal squamous cell carcinoma. J Clin Pathol. 2001; 54(1):42-7. PMC: 1731271. DOI: 10.1136/jcp.54.1.42. View

18.

Jenuwein T, Allis C . Translating the histone code. Science. 2001; 293(5532):1074-80. DOI: 10.1126/science.1063127. View

19.

Klein E, Assoian R . Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci. 2008; 121(Pt 23):3853-7. PMC: 4545630. DOI: 10.1242/jcs.039131. View

20.

Coluccia A, Vacca A, Dunach M, Mologni L, Redaelli S, Bustos V . Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J. 2007; 26(5):1456-66. PMC: 1817619. DOI: 10.1038/sj.emboj.7601485. View